{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:36:47Z","timestamp":1792715807536,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T00:00:00Z","timestamp":1548288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T00:00:00Z","timestamp":1548288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Understanding HIV remission in rare individuals who initiated antiretroviral therapy (ART) soon after infection and then discontinued, may inform HIV cure interventions. Here we describe features of virus and host of a perinatally HIV-1 infected child with long-term sustained virological control. The child received early limited ART in the Children with HIV Early antiRetroviral therapy (CHER) trial. At age 9.5 years, diagnostic tests for HIV are negative and the child has characteristics similar to uninfected children that include a high CD4:CD8 ratio, low T\u00a0cell activation and low CCR5 expression. Virus persistence (HIV-1 DNA and plasma RNA) is confirmed with sensitive methods, but replication-competent virus is not detected. The child has weak HIV-specific antibody and T\u00a0cell responses. Furthermore, we determine his <jats:italic>HLA<\/jats:italic> and <jats:italic>KIR<\/jats:italic> genotypes. This case aids in understanding post-treatment control and may help design of future intervention strategies.<\/jats:p>","DOI":"10.1038\/s41467-019-08311-0","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T11:05:12Z","timestamp":1548327912000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["A child with perinatal HIV infection and long-term sustained virological control following antiretroviral treatment cessation"],"prefix":"10.1038","volume":"10","author":[{"given":"Avy","family":"Violari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark F.","family":"Cotton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana B.","family":"Schramm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Paximadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayne","family":"Loubser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Shalekoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Da Costa Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kennedy","family":"Otwombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afaaf","family":"Liberty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel","family":"Babiker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Gibb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline T.","family":"Tiemessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,24]]},"reference":[{"key":"8311_CR1","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","volume":"278","author":"D Finzi","year":"1997","unstructured":"Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295\u20131300 (1997).","journal-title":"Science"},{"key":"8311_CR2","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1126\/science.278.5341.1291","volume":"278","author":"JK Wong","year":"1997","unstructured":"Wong, J. K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291\u20131295 (1997).","journal-title":"Science"},{"key":"8311_CR3","doi-asserted-by":"publisher","first-page":"8869","DOI":"10.1073\/pnas.95.15.8869","volume":"95","author":"TW Chun","year":"1998","unstructured":"Chun, T. W. et al. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc. Natl Acad. Sci. USA 95, 8869\u20138873 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"8311_CR4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ebiom.2016.07.024","volume":"11","author":"J Ananworanich","year":"2016","unstructured":"Ananworanich, J. et al. HIV DNA set point is rapidly established in acute HIV infection and dramatically reduced by early ART. EBioMedicine 11, 68\u201372 (2016).","journal-title":"EBioMedicine"},{"key":"8311_CR5","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/s41591-018-0026-6","volume":"24","author":"DJ Colby","year":"2018","unstructured":"Colby, D.J. et al. Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. Nat. Med. 24, 923\u2013926 (2018).","journal-title":"Nat. Med."},{"key":"8311_CR6","doi-asserted-by":"publisher","first-page":"e1002417","DOI":"10.1371\/journal.pmed.1002417","volume":"14","author":"TJ Henrich","year":"2017","unstructured":"Henrich, T. J. et al. HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: an observational study. PLoS Med. 14, e1002417 (2017).","journal-title":"PLoS Med."},{"key":"8311_CR7","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/ni.3152","volume":"16","author":"TW Chun","year":"2015","unstructured":"Chun, T. W., Moir, S. & Fauci, A. S. HIV reservoirs as obstacles and opportunities for an HIV cure. Nat. Immunol. 16, 584\u2013589 (2015).","journal-title":"Nat. Immunol."},{"key":"8311_CR8","doi-asserted-by":"publisher","first-page":"e1003211","DOI":"10.1371\/journal.ppat.1003211","volume":"9","author":"A Saez-Cirion","year":"2013","unstructured":"Saez-Cirion, A. et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 9, e1003211 (2013).","journal-title":"PLoS Pathog."},{"key":"8311_CR9","doi-asserted-by":"publisher","first-page":"e78287","DOI":"10.1371\/journal.pone.0078287","volume":"8","author":"W Stohr","year":"2013","unstructured":"Stohr, W. et al. Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy. PLoS ONE 8, e78287 (2013).","journal-title":"PLoS ONE"},{"key":"8311_CR10","doi-asserted-by":"publisher","first-page":"e03821","DOI":"10.7554\/eLife.03821","volume":"3","author":"JP Williams","year":"2014","unstructured":"Williams, J. P. et al. HIV-1 DNA predicts disease progression and post-treatment virological control. eLife 3, e03821 (2014).","journal-title":"eLife"},{"key":"8311_CR11","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1001\/archinternmed.2012.2719","volume":"172","author":"S Lodi","year":"2012","unstructured":"Lodi, S. et al. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch. Intern. Med 172, 1252\u20131255 (2012).","journal-title":"Arch. Intern. Med"},{"key":"8311_CR12","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1097\/QAD.0b013e328305bd77","volume":"22","author":"R Steingrover","year":"2008","unstructured":"Steingrover, R. et al. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS 22, 1583\u20131588 (2008).","journal-title":"AIDS"},{"key":"8311_CR13","doi-asserted-by":"publisher","first-page":"ofv144","DOI":"10.1093\/ofid\/ofv144","volume":"2","author":"S Kinloch-de Loes","year":"2015","unstructured":"Kinloch-de Loes, S. et al. Aviremia 10 years postdiscontinuation of antiretroviral therapy initiated during primary human immunodeficiency virus-1 infection and association with Gag-specific T-cell responses. Open Forum Infect. Dis. 2, ofv144 (2015).","journal-title":"Open Forum Infect. Dis."},{"key":"8311_CR14","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1097\/QAD.0000000000001472","volume":"31","author":"JH McMahon","year":"2017","unstructured":"McMahon, J. H. et al. Post-treatment control in an adult with perinatally acquired HIV following cessation of antiretroviral therapy. AIDS 31, 1344\u20131346 (2017).","journal-title":"AIDS"},{"key":"8311_CR15","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/QAI.0000000000001393","volume":"75","author":"MJ Perkins","year":"2017","unstructured":"Perkins, M. J. et al. Brief Report: prevalence of posttreatment controller phenotype is rare in HIV-infected persons after stopping antiretroviral therapy. J. Acquir. Immune Def. Syndr. 75, 364\u2013369 (2017).","journal-title":"J. Acquir. Immune Def. Syndr."},{"key":"8311_CR16","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/QAD.0000000000001743","volume":"32","author":"F Maggiolo","year":"2018","unstructured":"Maggiolo, F., Di Filippo, E., Comi, L. & Callegaro, A. Post-treatment controllers after treatment interruption in chronically HIV-infected patients. AIDS 32, 623\u2013628 (2018).","journal-title":"AIDS"},{"key":"8311_CR17","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1086\/433188","volume":"41","author":"O Lambotte","year":"2005","unstructured":"Lambotte, O. et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin. Infect. Dis. 41, 1053\u20131056 (2005).","journal-title":"Clin. Infect. Dis."},{"key":"8311_CR18","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.immuni.2007.08.010","volume":"27","author":"SG Deeks","year":"2007","unstructured":"Deeks, S. G. & Walker, B. D. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27, 406\u2013416 (2007).","journal-title":"Immunity"},{"key":"8311_CR19","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1056\/NEJMoa1302976","volume":"369","author":"D Persaud","year":"2013","unstructured":"Persaud, D. et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N. Engl. J. Med. 369, 1828\u20131835 (2013).","journal-title":"N. Engl. J. Med."},{"key":"8311_CR20","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1056\/NEJMc1413931","volume":"372","author":"K Luzuriaga","year":"2015","unstructured":"Luzuriaga, K. et al. Viremic relapse after HIV-1 remission in a perinatally infected child. N. Engl. J. Med. 372, 786\u2013788 (2015).","journal-title":"N. Engl. J. Med."},{"key":"8311_CR21","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1016\/S2352-3018(15)00232-5","volume":"3","author":"P Frange","year":"2016","unstructured":"Frange, P. et al. HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report. Lancet HIV 3, e49\u2013e54 (2016).","journal-title":"Lancet HIV"},{"key":"8311_CR22","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1056\/NEJMoa0800971","volume":"359","author":"A Violari","year":"2008","unstructured":"Violari, A. et al. Early antiretroviral therapy and mortality among HIV-infected infants. N. Engl. J. Med. 359, 2233\u20132244 (2008).","journal-title":"N. Engl. J. Med."},{"key":"8311_CR23","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/S0140-6736(13)61409-9","volume":"382","author":"MF Cotton","year":"2013","unstructured":"Cotton, M. F. et al. Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial. Lancet 382, 1555\u20131563 (2013).","journal-title":"Lancet"},{"key":"8311_CR24","doi-asserted-by":"publisher","first-page":"e16541","DOI":"10.1371\/journal.pone.0016541","volume":"6","author":"M Paximadis","year":"2011","unstructured":"Paximadis, M. et al. KIR-HLA and maternal-infant HIV-1 transmission in sub-Saharan Africa. PLoS ONE 6, e16541 (2011).","journal-title":"PLoS ONE"},{"key":"8311_CR25","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.clim.2013.09.005","volume":"149","author":"HA Hong","year":"2013","unstructured":"Hong, H. A., Paximadis, M., Gray, G. E., Kuhn, L. & Tiemessen, C. T. KIR2DS4 allelic variants: differential effects on in utero and intrapartum HIV-1 mother-to-child transmission. Clin. Immunol. 149, 498\u2013508 (2013).","journal-title":"Clin. Immunol."},{"key":"8311_CR26","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/infdis\/jiu297","volume":"210","author":"K Luzuriaga","year":"2014","unstructured":"Luzuriaga, K. et al. HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment. J. Infect. Dis. 210, 1529\u20131538 (2014).","journal-title":"J. Infect. Dis."},{"key":"8311_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/infdis\/jiu827","volume":"212","author":"GU van Zyl","year":"2015","unstructured":"van Zyl, G. U. et al. Early antiretroviral therapy in South African children reduces HIV-1-infected cells and cell-associated HIV-1 RNA in blood mononuclear cells. J. Infect. Dis. 212, 39\u201343 (2015).","journal-title":"J. Infect. Dis."},{"key":"8311_CR28","doi-asserted-by":"publisher","first-page":"e0195514","DOI":"10.1371\/journal.pone.0195514","volume":"13","author":"L Kuhn","year":"2018","unstructured":"Kuhn, L. et al. Age at antiretroviral therapy initiation and cell-associated HIV-1 DNA levels in HIV-1-infected children. PLoS ONE 13, e0195514 (2018).","journal-title":"PLoS ONE"},{"key":"8311_CR29","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1097\/QAD.0000000000000677","volume":"29","author":"L Kuhn","year":"2015","unstructured":"Kuhn, L. et al. Young age at start of antiretroviral therapy and negative HIV antibody results in HIV-infected children when suppressed. AIDS 29, 1053\u20131060 (2015).","journal-title":"AIDS"},{"key":"8311_CR30","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S1473-3099(15)00087-0","volume":"15","author":"H Payne","year":"2015","unstructured":"Payne, H. et al. Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysis. Lancet Infect. Dis. 15, 803\u2013809 (2015).","journal-title":"Lancet Infect. Dis."},{"key":"8311_CR31","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1093\/cid\/ciw365","volume":"63","author":"MS de Souza","year":"2016","unstructured":"de Souza, M. S. et al. Initiation of antiretroviral therapy during acute HIV-1 infection leads to a high rate of nonreactive HIV serology. Clin. Infect. Dis. 63, 555\u2013561 (2016).","journal-title":"Clin. Infect. Dis."},{"key":"8311_CR32","doi-asserted-by":"publisher","first-page":"12449","DOI":"10.1128\/JVI.01708-08","volume":"82","author":"GD Tomaras","year":"2008","unstructured":"Tomaras, G. D. et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 82, 12449\u201312463 (2008).","journal-title":"J. Virol."},{"key":"8311_CR33","first-page":"336ra362","volume":"8","author":"R Zhang","year":"2016","unstructured":"Zhang, R. et al. Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages. Sci. Transl. Med 8, 336ra362 (2016).","journal-title":"Sci. Transl. Med"},{"key":"8311_CR34","doi-asserted-by":"publisher","first-page":"aab1253","DOI":"10.1126\/science.aab1253","volume":"349","author":"WB Williams","year":"2015","unstructured":"Williams, W. B. et al. HIV-1 vaccines. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. Science 349, aab1253 (2015).","journal-title":"Science"},{"key":"8311_CR35","doi-asserted-by":"publisher","first-page":"e0180245","DOI":"10.1371\/journal.pone.0180245","volume":"12","author":"R Nabi","year":"2017","unstructured":"Nabi, R. et al. Differences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapy. PLoS ONE 12, e0180245 (2017).","journal-title":"PLoS ONE"},{"key":"8311_CR36","doi-asserted-by":"publisher","first-page":"pii: e00700-17","DOI":"10.1128\/JVI.00700-17","volume":"91","author":"V Madhavi","year":"2017","unstructured":"Madhavi, V. et al. Env- and Vpu-specific antibody-dependent cellular cytotoxicity responses associated with Elite control of HIV. J. Virol. 91, pii: e00700-17 (2017).","journal-title":"J. Virol."},{"key":"8311_CR37","doi-asserted-by":"publisher","first-page":"5914","DOI":"10.4049\/jimmunol.0900419","volume":"182","author":"CT Tiemessen","year":"2009","unstructured":"Tiemessen, C. T. et al. Cutting edge: unusual NK cell responses to HIV-1 peptides are associated with protection against maternal-infant transmission of HIV-1. J. Immunol. 182, 5914\u20135918 (2009).","journal-title":"J. Immunol."},{"key":"8311_CR38","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1086\/656535","volume":"202","author":"CT Tiemessen","year":"2010","unstructured":"Tiemessen, C. T. et al. Natural killer cells that respond to human immunodeficiency virus type 1 (HIV-1) peptides are associated with control of HIV-1 infection. J. Infect. Dis. 202, 1444\u20131453 (2010).","journal-title":"J. Infect. Dis."},{"key":"8311_CR39","first-page":"207","volume":"24","author":"MC Re","year":"2001","unstructured":"Re, M. C. et al. Relationships between the presence of anti-Tat antibody, DNA and RNA viral load. N. Microbiol. 24, 207\u2013215 (2001).","journal-title":"N. Microbiol."},{"key":"8311_CR40","first-page":"282","volume":"1","author":"JF Zagury","year":"1998","unstructured":"Zagury, J. F. et al. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J. Hum. Virol. 1, 282\u2013292 (1998).","journal-title":"J. Hum. Virol."},{"key":"8311_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1647-3","volume":"16","author":"F Nicoli","year":"2016","unstructured":"Nicoli, F. et al. Association between different anti-Tat antibody isotypes and HIV disease progression: data from an African cohort. BMC Infect. Dis. 16, 344 (2016).","journal-title":"BMC Infect. Dis."},{"key":"8311_CR42","first-page":"115","volume":"17","author":"A Cafaro","year":"2018","unstructured":"Cafaro, A. et al. cART intensification by the HIV-1 Tat B clade vaccine: progress to phase III efficacy studies. Expert. Rev. Vaccin. 17, 115\u2013126 (2018).","journal-title":"Expert. Rev. Vaccin."},{"key":"8311_CR43","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1089\/088922201753197105","volume":"17","author":"N Ngo-Giang-Huong","year":"2001","unstructured":"Ngo-Giang-Huong, N. et al. HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression. AIDS Res. Hum. Retrovir. 17, 1435\u20131446 (2001).","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"8311_CR44","doi-asserted-by":"publisher","first-page":"9053","DOI":"10.1128\/JVI.00721-13","volume":"87","author":"P Pala","year":"2013","unstructured":"Pala, P. et al. Quantitative and qualitative differences in the T cell response to HIV in uninfected Ugandans exposed or unexposed to HIV-infected partners. J. Virol. 87, 9053\u20139063 (2013).","journal-title":"J. Virol."},{"key":"8311_CR45","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1097\/QAD.0b013e328329c784","volume":"23","author":"S Shalekoff","year":"2009","unstructured":"Shalekoff, S. et al. Identification of human immunodeficiency virus-1 specific CD8+ and CD4+ T cell responses in perinatally-infected infants and their mothers. AIDS 23, 789\u2013798 (2009).","journal-title":"AIDS"},{"key":"8311_CR46","doi-asserted-by":"publisher","first-page":"6984","DOI":"10.1128\/JVI.74.15.6984-6991.2000","volume":"74","author":"K Luzuriaga","year":"2000","unstructured":"Luzuriaga, K. et al. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. J. Virol. 74, 6984\u20136991 (2000).","journal-title":"J. Virol."},{"key":"8311_CR47","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1073\/pnas.1600097113","volume":"A113","author":"M Kim","year":"2016","unstructured":"Kim, M. & Siliciano, R. F. Reservoir expansion by T-cell proliferation may be another barrier to curing HIV infection. Proc. Natl Acad. Sci. USA A113, 1692\u20131694 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"8311_CR48","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1084\/jem.20162123","volume":"214","author":"EM Leitman","year":"2017","unstructured":"Leitman, E. M. et al. Role of HIV-specific CD8(+) T cells in pediatric HIV cure strategies after widespread early viral escape. J. Exp. Med. 214, 3239\u20133261 (2017).","journal-title":"J. Exp. Med."},{"key":"8311_CR49","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nature03113","volume":"432","author":"P Kiepiela","year":"2004","unstructured":"Kiepiela, P. et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432, 769\u2013775 (2004).","journal-title":"Nature"},{"key":"8311_CR50","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1146\/annurev.med.54.101601.152346","volume":"54","author":"M Carrington","year":"2003","unstructured":"Carrington, M. & O\u2019Brien, S. J. The influence of HLA genotype on AIDS. Ann. Rev. Med. 54, 535\u2013551 (2003).","journal-title":"Ann. Rev. Med."},{"key":"8311_CR51","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1182\/blood-2008-10-182709","volume":"113","author":"AL Ferre","year":"2009","unstructured":"Ferre, A. L. et al. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 113, 3978\u20133989 (2009).","journal-title":"Blood"},{"key":"8311_CR52","doi-asserted-by":"publisher","first-page":"296ra112","DOI":"10.1126\/scitranslmed.aab4005","volume":"7","author":"HA Prentice","year":"2015","unstructured":"Prentice, H. A. et al. HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. Sci. Transl. Med. 7, 296ra112 (2015).","journal-title":"Sci. Transl. Med."},{"key":"8311_CR53","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11904-011-0106-4","volume":"9","author":"F Porichis","year":"2012","unstructured":"Porichis, F. & Kaufmann, D. E. Role of PD-1 in HIV pathogenesis and as target for therapy. Curr. HIV\/AIDS Rep. 9, 81\u201390 (2012).","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"8311_CR54","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1093\/cid\/ciw409","volume":"63","author":"NI Wada","year":"2016","unstructured":"Wada, N. I. et al. Inflammatory biomarkers and mortality risk among HIV-suppressed men: a Multisite Prospective Cohort Study. Clin. Inf. Dis. 63, 984\u2013990 (2016).","journal-title":"Clin. Inf. Dis."},{"key":"8311_CR55","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.it.2007.09.002","volume":"28","author":"A Saez-Cirion","year":"2007","unstructured":"Saez-Cirion, A., Pancino, G., Sinet, M., Venet, A. & Lambotte, O. HIV controllers: how do they tame the virus? Trends Immunol. 28, 532\u2013540 (2007).","journal-title":"Trends Immunol."},{"key":"8311_CR56","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1126\/science.1217550","volume":"335","author":"A Chahroudi","year":"2012","unstructured":"Chahroudi, A., Bosinger, S. E., Vanderford, T. H., Paiardini, M. & Silvestri, G. Natural SIV hosts: showing AIDS the door. Science 335, 1188\u20131193 (2012).","journal-title":"Science"},{"key":"8311_CR57","doi-asserted-by":"publisher","first-page":"358ra125","DOI":"10.1126\/scitranslmed.aag1048","volume":"8","author":"M Muenchhoff","year":"2016","unstructured":"Muenchhoff, M. et al. Nonprogressing HIV-infected children share fundamental immunological features of nonpathogenic SIV infection. Sci. Transl. Med 8, 358ra125 (2016).","journal-title":"Sci. Transl. Med"},{"key":"8311_CR58","doi-asserted-by":"publisher","unstructured":"Ramteke, S. M. et al. Patterns of growth, body composition, and lipid profiles in a South African Cohort of human immunodeficiency virus-infected and uninfected children: a cross-sectional study. J. Pediatr. Infect. Dis. Soc. https:\/\/doi.org\/10.1093\/jpids\/pix026 (2017).","DOI":"10.1093\/jpids\/pix026"},{"key":"8311_CR59","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1080\/09540121.2016.1224310","volume":"29","author":"PM Murnane","year":"2017","unstructured":"Murnane, P. M. et al. Extent of disclosure: what perinatally HIV-infected children have been told about their own HIV status. AIDS Care 29, 378\u2013386 (2017).","journal-title":"AIDS Care"},{"key":"8311_CR60","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1128\/JCM.00055-08","volume":"46","author":"AO Pasternak","year":"2008","unstructured":"Pasternak, A. O. et al. Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA. J. Clin. Microbiol. 46, 2206\u20132211 (2008).","journal-title":"J. Clin. Microbiol."},{"key":"8311_CR61","doi-asserted-by":"publisher","first-page":"e85999","DOI":"10.1371\/journal.pone.0085999","volume":"9","author":"M Kiselinova","year":"2014","unstructured":"Kiselinova, M. et al. Comparison of droplet digital PCR and seminested real-time PCR for quantification of cell-associated HIV-1 RNA. PLoS ONE 9, e85999 (2014).","journal-title":"PLoS ONE"},{"key":"8311_CR62","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1093\/molbev\/msm092","volume":"24","author":"K Tamura","year":"2007","unstructured":"Tamura, K., Dudley, J., Nei, M. & Kumar, S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol. Biol. Evol. 24, 1596\u20131599 (2007).","journal-title":"Mol. Biol. Evol."},{"key":"8311_CR63","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/978-1-4939-3046-3_16","volume":"1354","author":"GM Laird","year":"2016","unstructured":"Laird, G. M., Rosenbloom, D. I., Lai, J., Siliciano, R. F. & Siliciano, J. D. Measuring the frequency of latent HIV-1 in resting CD4(+) T cells using a limiting dilution coculture assay. Methods Mol. Biol. 1354, 239\u2013253 (2016).","journal-title":"Methods Mol. Biol."},{"key":"8311_CR64","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1089\/08892220050058344","volume":"16","author":"M Baba","year":"2000","unstructured":"Baba, M., Miyake, H., Okamoto, M., Iizawa, Y. & Okonogi, K. Establishment of a CCR5-expressing T-lymphoblastoid cell line highly susceptible to R5 HIV type 1. AIDS Res. Hum. Retrovir. 16, 935\u2013941 (2000).","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"8311_CR65","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1126\/science.3014648","volume":"233","author":"S Gartner","year":"1986","unstructured":"Gartner, S. et al. The role of mononuclear phagocytes in HTLV-III\/LAV infection. Science 233, 215\u2013219 (1986).","journal-title":"Science"},{"key":"8311_CR66","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jim.2012.09.007","volume":"386","author":"EP Brown","year":"2012","unstructured":"Brown, E. P. et al. High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. J. Immunol. Methods 386, 117\u2013123 (2012).","journal-title":"J. Immunol. Methods"},{"key":"8311_CR67","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.humimm.2017.05.006","volume":"78","author":"NL Gentle","year":"2017","unstructured":"Gentle, N. L., Loubser, S., Paximadis, M., Puren, A. & Tiemessen, C. T. Killer-cell immunoglobulin-like receptor (KIR) and human leukocyte antigen (HLA) class I genetic diversity in four South African populations. Hum. Immunol. 78, 503\u2013509 (2017).","journal-title":"Hum. Immunol."},{"key":"8311_CR68","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1101\/gr.137976.112","volume":"22","author":"W Jiang","year":"2012","unstructured":"Jiang, W. et al. Copy number variation leads to considerable diversity for B but not A haplotypes of the human KIR genes encoding NK cell receptors. Genome Res. 22, 1845\u20131854 (2012).","journal-title":"Genome Res."},{"key":"8311_CR69","doi-asserted-by":"publisher","first-page":"e1001208","DOI":"10.1371\/journal.pbio.1001208","volume":"9","author":"K Pelak","year":"2011","unstructured":"Pelak, K. et al. Copy number variation of KIR genes influences HIV-1 control. PLoS Biol. 9, e1001208 (2011).","journal-title":"PLoS Biol."},{"key":"8311_CR70","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/QAD.0b013e3283270b3f","volume":"23","author":"L Shostakovich-Koretskaya","year":"2009","unstructured":"Shostakovich-Koretskaya, L. et al. Combinatorial content of CCL3L and CCL4L gene copy numbers influence HIV-AIDS susceptibility in Ukrainian children. AIDS 23, 679\u2013688 (2009).","journal-title":"AIDS"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-08311-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-08311-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-08311-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T19:33:09Z","timestamp":1671219189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-08311-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,24]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["8311"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-08311-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,24]]},"assertion":[{"value":"16 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"412"}}